Literature DB >> 23537575

Design of pH responsive clickable prodrugs applied to histone deacetylase inhibitors: a new strategy for anticancer therapy.

Régis Delatouche1, Iza Denis, Marion Grinda, Fatima El Bahhaj, Estelle Baucher, Floraine Collette, Valérie Héroguez, Marc Grégoire, Christophe Blanquart, Philippe Bertrand.   

Abstract

The aim of this study was to develop clickable prodrugs bearing a tunable pH responsive linker designed for acidic pH-mediated release of histone deacetylase inhibitors. HDACi are an important class of molecules belonging to the epigenetic modulators used for innovative cancer strategies. The behavior of these prodrugs was determined by a bioluminescence resonance energy transfer assay in living tumor cells. This work demonstrated that this innovative type of clickable prodrugs entered cancer cells and showed restored anti proliferative properties attributed to the effective release of the HDAC inhibitors. A correlation between kinetic studies, dose responses, and biological activities was obtained, making such clickable prodrugs good candidates for new strategies in epigenetic-oriented anticancer therapies.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bioluminescence; Cancer; Click chemistry; Histone acetylation; Prodrug; pH response

Mesh:

Substances:

Year:  2013        PMID: 23537575     DOI: 10.1016/j.ejpb.2013.03.006

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  9 in total

1.  Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.

Authors:  Samuel Bouchet; Camille Linot; Dusan Ruzic; Danica Agbaba; Benoit Fouchaq; Joëlle Roche; Katarina Nikolic; Christophe Blanquart; Philippe Bertrand
Journal:  ACS Med Chem Lett       Date:  2019-05-09       Impact factor: 4.345

2.  Synthesis and activity of tumor-homing peptide iRGD and histone deacetylase inhibitor valproic acid conjugate.

Authors:  Zheng-Hong Peng; Jindřich Kopeček
Journal:  Bioorg Med Chem Lett       Date:  2014-03-12       Impact factor: 2.823

3.  Histone Deacetylase Inhibitor (HDACi) Conjugated Polycaprolactone for Combination Cancer Therapy.

Authors:  Ruvanthi N Kularatne; Katherine E Washington; Chandima Bulumulla; Erika L Calubaquib; Michael C Biewer; David Oupicky; Mihaela C Stefan
Journal:  Biomacromolecules       Date:  2018-02-27       Impact factor: 6.988

4.  Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor Therapy.

Authors:  Fatima El Bahhaj; Iza Denis; Loic Pichavant; Régis Delatouche; Floraine Collette; Camille Linot; Daniel Pouliquen; Marc Grégoire; Valérie Héroguez; Christophe Blanquart; Philippe Bertrand
Journal:  Theranostics       Date:  2016-03-25       Impact factor: 11.556

Review 5.  Epigenetics in cancer therapy and nanomedicine.

Authors:  Annalisa Roberti; Adolfo F Valdes; Ramón Torrecillas; Mario F Fraga; Agustin F Fernandez
Journal:  Clin Epigenetics       Date:  2019-05-16       Impact factor: 6.551

Review 6.  The ROMP: A Powerful Approach to Synthesize Novel pH-Sensitive Nanoparticles for Tumor Therapy.

Authors:  Philippe Bertrand; Christophe Blanquart; Valérie Héroguez
Journal:  Biomolecules       Date:  2019-02-12

7.  Supramolecular Caffeic Acid and Bortezomib Nanomedicine: Prodrug Inducing Reactive Oxygen Species and Inhibiting Cancer Cell Survival.

Authors:  Ludwig Erik Aguilar; Se Rim Jang; Chan Hee Park; Kang Min Lee
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

8.  A facile route to form self-carried redox-responsive vorinostat nanodrug for effective solid tumor therapy.

Authors:  Leiqiang Han; Tianqi Wang; Jingliang Wu; Xiaolan Yin; Hao Fang; Na Zhang
Journal:  Int J Nanomedicine       Date:  2016-11-11

9.  Nitroreductase-Mediated Release of Inhibitors of Lysine-Specific Demethylase 1 (LSD1) from Prodrugs in Transfected Acute Myeloid Leukaemia Cells.

Authors:  Eva-Maria Herrlinger; Mirjam Hau; Desiree Melanie Redhaber; Gabriele Greve; Dominica Willmann; Simon Steimle; Michael Müller; Michael Lübbert; Christoph Cornelius Miething; Roland Schüle; Manfred Jung
Journal:  Chembiochem       Date:  2020-04-27       Impact factor: 3.164

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.